PAP
RPRX icon

Persistent Asset Partners’s Royalty Pharma RPRX Stock Holding History

Persistent Asset Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Sell
5,178
-1,416
-21% -$62K 0.09% 171
2025
Q4 		$255K Buy
+6,594
New +$251K 0.11% 197

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Persistent Asset Partners's RPRX Position: Q1 2026 in Review

Persistent Asset Partners reduced its Royalty Pharma (RPRX) stake by 21% in Q1 2026, selling an estimated $62K and leaving 5,178 shares worth $248K. The position accounts for 0.09% of the portfolio, ranked #171.

Persistent Asset Partners first reported a position in RPRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $255K in Q4 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Persistent Asset Partners held 5,178 shares of Royalty Pharma worth $248K as of Q1 2026.
  • Persistent Asset Partners sold 1,416 Royalty Pharma shares in Q1 2026, an estimated $62K.
  • Royalty Pharma made up 0.09% of Persistent Asset Partners's portfolio in Q1 2026, its #171 holding.
  • Persistent Asset Partners first reported a position in Royalty Pharma in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Royalty Pharma position peaked at $255K in Q4 2025.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.